|
IPC, NIPER Guwahati to hold conclave on IP on Aug-27 to focus on drug quality, regulatory compliance
|
|
Shardul Nautiyal, Mumbai
August 01 , 2026
|
|
|
The Indian Pharmacopoeia Commission (IPC), Ghaziabad, in collaboration with the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, will organise a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 on August 27, 2026, bringing together regulators, scientists, academicians and pharmaceutical industry representatives to deliberate on quality standards, regulatory compliance and developments in phytopharmaceuticals.
The one-day conclave, to be held at the Mini Conference Hall of NIPER, Guwahati, will focus on the theme, "Advancing Quality, Safety, and Innovation in Drugs and Phytopharmaceuticals," with discussions aimed at strengthening awareness and implementation of the latest pharmacopoeial standards. It will discuss recent developments in pharmacopoeial standards, quality assurance and regulatory requirements governing drugs and phytopharmaceuticals.
According to the organisers, the conclave will focus on updates incorporated in the IP 2026 and their implications for pharmaceutical manufacturers, quality professionals and regulatory personnel. The discussions are intended to improve understanding of revised standards and encourage their effective adoption across the industry.
A major area of discussion will be the role of Indian Pharmacopoeia Reference Substances (IPRS) in strengthening the quality assessment of phytopharmaceuticals. Experts are expected to explain how reference substances support standardisation, analytical testing and quality control, thereby helping manufacturers maintain consistency in products derived from plant-based sources.
The programme will also examine the growing importance of elemental impurities in drugs and phytopharmaceuticals. Scientific sessions will address approaches for monitoring and controlling elemental impurities to ensure product safety, regulatory compliance and patient protection in line with pharmacopoeial requirements.
Another key session will focus on phytopharmaceutical development, highlighting the integration of traditional medicinal knowledge with modern scientific research. Experts are expected to discuss how evidence-based approaches, quality evaluation and scientific validation can support the development of phytopharmaceutical products while maintaining accepted quality standards.
The conclave will also deliberate on safety considerations associated with Schedule M and Schedule Y in relation to the manufacturing of phytopharmaceuticals. These discussions will cover regulatory expectations concerning manufacturing practices, quality systems and compliance requirements that manufacturers need to address while developing and producing such products.
Officials associated with the programme said the conclave has been designed to encourage dialogue between regulators, researchers and industry stakeholders, enabling participants to understand recent regulatory developments and scientific advances related to the Indian Pharmacopoeia 2026. They added that interactive technical sessions will provide an opportunity for participants to engage with subject experts and seek clarification on practical aspects of implementation.
The event is expected to attract pharmaceutical manufacturers, quality assurance and quality control professionals, regulatory affairs personnel, researchers, academicians, industry stakeholders and students pursuing B.Pharm, M.Pharm and Pharm.D programmes. Through technical presentations and interactive discussions, the conclave aims to strengthen awareness of pharmacopoeial standards, promote regulatory compliance and support the adoption of scientific practices that contribute to the quality, safety and innovation of drugs and phytopharmaceuticals in India.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|